SEC Form 4 · accession 0001214659-26-011596
Aquestive Therapeutics, Inc. · AQST
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Sherry Korczynski
Officer — Chief Commercial Officer
Period of report
Sep 9, 2026
Accepted (ET)
Sep 11, 2026 · 11:07 am EDT
Rule 10b5-1 plan
yes — trade under a plan
Issuer CIK
0001398733
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Sep 9, 2026 | M | 8,750 | $2.65 | A | 244,439 | D | |
| Common Stock | Sep 9, 2026 | S | 8,750 | $5.22 | D | 235,689 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Non-Qualified Stock Option (right to buy)F2 | $2.65 | Sep 9, 2026 | M | 8,750 | D | — | Mar 7, 2035 | Common Stock | 8,750 | 26,250 | D |
Explanation of responses
- F1The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 Trading Plan previously adopted by the reporting person in this Form 4.
- F2The options will vest in three annual installments with 25% on the 1st installment, 25% on the 2nd installment and 50% on the 3rd installment.